X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs PFIZER - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES PFIZER DIVIS LABORATORIES/
PFIZER
 
P/E (TTM) x 33.1 33.4 99.0% View Chart
P/BV x 5.4 5.0 107.9% View Chart
Dividend Yield % 0.9 0.8 121.4%  

Financials

 DIVIS LABORATORIES   PFIZER
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
PFIZER
Mar-17
DIVIS LABORATORIES/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,2222,055 59.5%   
Low Rs7841,651 47.5%   
Sales per share (Unadj.) Rs153.1429.8 35.6%  
Earnings per share (Unadj.) Rs39.973.6 54.3%  
Cash flow per share (Unadj.) Rs44.687.4 51.0%  
Dividends per share (Unadj.) Rs10.0020.00 50.0%  
Dividend yield (eoy) %1.01.1 92.4%  
Book value per share (Unadj.) Rs201.8528.7 38.2%  
Shares outstanding (eoy) m265.4745.75 580.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.64.3 151.9%   
Avg P/E ratio x25.125.2 99.7%  
P/CF ratio (eoy) x22.521.2 106.1%  
Price / Book Value ratio x5.03.5 141.8%  
Dividend payout %25.027.2 92.1%   
Avg Mkt Cap Rs m266,26684,777 314.1%   
No. of employees `0009.72.8 342.9%   
Total wages/salary Rs m4,6873,039 154.2%   
Avg. sales/employee Rs Th4,175.06,925.9 60.3%   
Avg. wages/employee Rs Th481.51,070.4 45.0%   
Avg. net profit/employee Rs Th1,089.31,186.3 91.8%   
INCOME DATA
Net Sales Rs m40,64319,663 206.7%  
Other income Rs m7491,012 74.0%   
Total revenues Rs m41,39220,674 200.2%   
Gross profit Rs m14,4603,491 414.2%  
Depreciation Rs m1,233629 196.0%   
Interest Rs m2310 235.4%   
Profit before tax Rs m13,9533,864 361.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,304 0.0%   
Tax Rs m3,3491,801 186.0%   
Profit after tax Rs m10,6043,368 314.9%  
Gross profit margin %35.617.8 200.4%  
Effective tax rate %24.046.6 51.5%   
Net profit margin %26.117.1 152.3%  
BALANCE SHEET DATA
Current assets Rs m40,10520,789 192.9%   
Current liabilities Rs m6,5957,870 83.8%   
Net working cap to sales %82.565.7 125.5%  
Current ratio x6.12.6 230.2%  
Inventory Days Days11960 198.4%  
Debtors Days Days8122 359.9%  
Net fixed assets Rs m19,9959,175 217.9%   
Share capital Rs m531458 116.0%   
"Free" reserves Rs m53,04323,731 223.5%   
Net worth Rs m53,57424,189 221.5%   
Long term debt Rs m025 0.0%   
Total assets Rs m61,58532,706 188.3%  
Interest coverage x618.4403.5 153.3%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.70.6 109.8%   
Return on assets %17.310.3 167.1%  
Return on equity %19.813.9 142.2%  
Return on capital %26.121.4 122.0%  
Exports to sales %00-   
Imports to sales %25.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259NA-   
Fx inflow Rs m35,38463 56,254.1%   
Fx outflow Rs m10,3994,067 255.7%   
Net fx Rs m24,985-4,004 -624.0%   
CASH FLOW
From Operations Rs m11,4933,288 349.5%  
From Investments Rs m-11,372-2,496 455.5%  
From Financial Activity Rs m-93-826 11.3%  
Net Cashflow Rs m28-35 -82.1%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 11.8 7.5 157.3%  
FIIs % 19.0 4.9 387.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 23.7 72.6%  
Shareholders   31,796 85,207 37.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   AUROBINDO PHARMA  MERCK LTD  GSK PHARMA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; Metal Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jun 20, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS